[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100243319":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":66,"collaborators":69,"id":72,"slug":32,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":32,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":32,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":32,"overallStatus":41,"whyStopped":32,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"90 mg\u002Fdl glucose clamp","EXPERIMENTAL","Glucose clamp intervention of 90 mg\u002Fdl maintained for 90 minutes.",[13],"Device: Glucose clamp",{"label":15,"type":10,"description":16,"interventionNames":17},"70 mg\u002Fdl glucose clamp","Glucose clamp intervention of 70 mg\u002Fdl maintained for 90 minutes.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"60 mg\u002Fdl glucose clamp","Glucose clamp intervention of 60 mg\u002Fdl maintained for 90 minutes.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"50 mg\u002Fdl glucose clamp","Glucose clamp intervention of 50 mg\u002Fdl maintained for 90 minutes.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DEVICE","Glucose clamp","Different levels of hypoglycemia",[23,19,15,9],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Maka Siamashvili, MD","CONTACT","410-706-5623","msiamashvili@som.umaryland.edu",[40,57],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Baltimore","Maryland","21201","United States",{"type":47,"coordinates":48},"Point",[49,50],-76.61219,39.29038,{"lat":50,"lon":49},[53,54],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":32},{"name":55,"role":56,"phone":32,"phoneExt":32,"email":32},"Stephen N Davis, MBBS","PRINCIPAL_INVESTIGATOR",{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},{"type":47,"coordinates":59},[49,50],{"lat":50,"lon":49},[62,63,65],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":32},{"name":64,"role":36,"phone":37,"phoneExt":32,"email":38},"Maka Hedrington, MD",{"name":55,"role":56,"phone":32,"phoneExt":32,"email":32},{"type":56,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Stephen N. Davis, MBBS","Chairman of Medicine",[70],{"name":71,"class":6},"Vanderbilt University","100243319",false,"NCT02445781","Differing Levels of Hypoglycemia","Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Differing Levels of Hypoglycemia","Inclusion Criteria:\n\n• Body mass index \\>21kg · m-2\n\nExclusion Criteria:\n\n* Pregnant women\n* Subjects unwilling or unable to comply with approved contraception measures\n* Subjects unable to give voluntary informed consent\n* Subjects on anticoagulant drugs, anemic or with known bleeding diatheses\n* Subjects with a history of severe, uncontrolled hypertension, heart disease, cerebrovascular incidents\n* Current tobacco use\n* Subjects with any known allergies to any of the study medications being used\n\nPhysical Exam Exclusion Criteria\n\n* Uncontrolled severe hypertension (i.e., blood pressure greater than 160\u002F100)\n* Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia)\n* Pneumonia treatment or hospitalization within 2 weeks prior to enrollment (study visit)\n* Hepatic failure \u002F jaundice\n* Renal failure\n* Cerebrovascular accident occurrence or hospitalization within 4 weeks prior to enrollment\n* Fever greater than 38.0 degrees C\n\nScreening Laboratory Tests Exclusion Criteria\n\n* Hematocrit lower than 32 %\n* White blood cell (WBC) count lower than 3 thou\u002Ful or greater than 14 thou\u002Ful\n* Liver function tests: serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) greater than twice upper limit of normal range\n* Alkaline phosphatase greater than 150U\u002FL\n* Total bilirubin (TBil) greater than 2 mg\u002Fdl\n* Estimated glomerular filtration rate (eGFR) less than 60 mL\u002Fmin\u002F1.73 m2\n* Positive human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C\n* Any abnormal cardiac response during multi-stage exercise test (if over 40 years of age)",true,"ALL","18 Years","55 Years",{"count":83,"type":84},32,"ESTIMATED","INTERVENTIONAL",[87],"EARLY_PHASE1","Hypoglycemia can produce a spectrum of pro-inflammatory and pro-atherothrombotic changes. To date no studies appear to have investigated the effects of differing levels of hypoglycemia on the vasculature and pro-atherothrombotic balance during hypoglycemia in healthy man. The specific aim of our study will be to determine the effects of differing levels of hypoglycemia on in-vivo vascular biologic mechanisms in a healthy population.",[90],"Hypoglycemia","2025-11-05",{"date":93,"type":94},"2025-11-10","ACTUAL",{"date":96,"type":32},"2015-07",{"date":98,"type":84},"2026-12",{"name":5,"class":6},2]